141 related articles for article (PubMed ID: 27613648)
1. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
Yata M; McLachlan AJ; Foster DJ; Hanzlicek AS; Beijerink NJ
J Vet Cardiol; 2016 Dec; 18(4):310-325. PubMed ID: 27613648
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral pimobendan in healthy cats.
Hanzlicek AS; Gehring R; Kukanich B; Kukanich KS; Borgarelli M; Smee N; Olson EE; Margiocco M
J Vet Cardiol; 2012 Dec; 14(4):489-96. PubMed ID: 23116650
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs.
Yata M; McLachlan AJ; Foster DJ; Page SW; Beijerink NJ
J Vet Pharmacol Ther; 2016 Feb; 39(1):45-53. PubMed ID: 25997373
[TBL] [Abstract][Full Text] [Related]
4. Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy.
Oldach MS; Ueda Y; Ontiveros ES; Fousse SL; Visser LC; Stern JA
BMC Vet Res; 2021 Feb; 17(1):89. PubMed ID: 33622315
[TBL] [Abstract][Full Text] [Related]
5. Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats.
Sugimoto K; Sugita K; Orito K; Fujii Y
Animals (Basel); 2022 Apr; 12(8):. PubMed ID: 35454228
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu KM; Shieh SM; Hu OY
Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).
Ozawa SM; Guzman DS; Hawkins MG; Diao SM; Masri AE; Gunther-Harrington CT; Knych HK
Am J Vet Res; 2022 Jan; 83(4):356-363. PubMed ID: 35038306
[TBL] [Abstract][Full Text] [Related]
8. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Hagemeijer F; Roth W; Brand HJ
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
[TBL] [Abstract][Full Text] [Related]
9. Effects of Intravenous Pimobendan on Cardiovascular Parameters in Healthy Sedated Cats.
Sugimoto K; Mochizuki Y; Akashi N; Kanda T; Hoshi F
Top Companion Anim Med; 2023; 53-54():100769. PubMed ID: 36813230
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
Bell ET; Devi JL; Chiu S; Zahra P; Whittem T
J Vet Pharmacol Ther; 2016 Feb; 39(1):54-61. PubMed ID: 25989021
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Pimobendan and Its Metabolite O-Desmethyl-Pimobendan Following Rectal Administration to Healthy Dogs.
Her J; Kuo KW; Winter RL; Cruz-Espindola C; Bacek LM; Boothe DM
Front Vet Sci; 2020; 7():423. PubMed ID: 32851013
[No Abstract] [Full Text] [Related]
12. Hemodynamic profile of the cardiotonic agent pimobendan.
van Meel JC; Diederen W
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
Chu KM; Hu OY; Shieh SM
Drug Metab Dispos; 1999 Jun; 27(6):701-9. PubMed ID: 10348800
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo.
von Meel JC
Arzneimittelforschung; 1985; 35(1A):284-8. PubMed ID: 4039168
[TBL] [Abstract][Full Text] [Related]
15. Echocardiographic assessment of right ventricular systolic function in conscious healthy dogs following a single dose of pimobendan versus atenolol.
Visser LC; Scansen BA; Brown NV; Schober KE; Bonagura JD
J Vet Cardiol; 2015 Sep; 17(3):161-72. PubMed ID: 26213150
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs.
Pichayapaiboon P; Tantisuwat L; Boonpala P; Saengklub N; Boonyarattanasoonthorn T; Khemawoot P; Kijtawornrat A
Front Vet Sci; 2021; 8():656902. PubMed ID: 34490386
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of pimobendan in healthy mature horses.
Afonso T; Giguère S; Rapoport G; Barton MH; Coleman AE
Equine Vet J; 2016 May; 48(3):352-6. PubMed ID: 25758404
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral administration of pimobendan in cats with heart failure.
Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
